Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cellectis/ISU ink TALENS deal

French genomics company Cellectis (Paris) has signed two exclusive licensing agreements with the US Iowa State University (Ames) giving Cellectis worldwide rights to use inventions related to transcription activator-like effector-nucleases (TALENs) and monomeric TALENs. The licences cover all uses of the TAL technologies in any field. TALENs are sequence-specific DNA nucleases that can be custom engineered to target and modify any gene of interest, in any species. The technology has broad applications in genome engineering including fundamental genetic research, crop improvement, and treatment of human genetic diseases.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG006830

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel